DOCSLIB.ORG

Laboratory Services and Procedures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laboratory Services and Procedures NORTH OAKS DEPARTMENT OF LABORATORIES Services & Procedures Update The following is a list of services most frequently utilized by clinics and physicians. If you have other test requests, please contact the Department of Laboratories for details at (985) 230-6165. The North Oaks Medical Center Department of Laboratories is one of more than 8,000 CAP-accredited laboratories worldwide, and has achieved this designation since 1996. The Laboratory’s Blood Bank has been AABB-accredited since 1974 and is currently among nearly 2,000 similar facilities worldwide. CSF Glucose Magnesium CHEMISTRY CSF Lactic Acid Microalbumin (Random) Access CK-MB CSF Protein NPA (B-type Natriuretic Peptide) Acetaminophen Digoxin Phenobarbitol Albumin Electrolyte Panel Phenytoin Alcohol Estradiol Phosphorus Alkaline Phosphatase Ferritin Potassium ALT Folate (Serum) Ammonia Free Thyroxine Index Prealbumin Amylase FT3 Prostate Specific Antigen AST Gentamycin PTH (INTACT) Basic Metabolic Panel Glucose Renal Panel BHCG Glucose - Point of Care Salicylate Bilirubin 1 Hour - Post Glucola Sodium Direct 2 Hour - Post Prandial Indirect GGT T3 Uptake Neonatal Glucose Tolerance Test T4 Free & Total Total (GTT: includes fasting and other times as indicated) Theophylline BUN 2 Hour TIBC C3 3 Hour (Calculated % Saturation with Iron and Transferrin) 4 Hour C4 5 Hour Total Protein Calcium Haptoglobin Total Testosterone Carbamazepine Hemoglobin A1C Triglycerides Carbon Dioxide Hepatic Function Panel Troponin I Cholesterol Uric Acid LDL IgA HDL IgG Urine HDL/LDL Hypersensitive hTSH Urea (Nitrogen - 24 hour) Total (Human Thyroid Stimulating Hormone) Amylase (2 Hour) Potassium (Random & 24 hour) Chloride IgM Protein (Random & 24 hour) Comprehensive Metabolic Panel Iron Sodium (Random & 24 hour) Cortisol (Serum) Lactic Acid Creatinine (Random & 24 hour) CPK Lactose Tolerance Urine Drug Screens Creatinine Clearance LDH Valproic Acid Creatinine Lipase Vancomycin CRP Lipid Profile Vitamin B - 12 CRPH Lithium For further information, please contact the North Oaks Department of Laboratories at (985) 230-6165. NORTH OAKS DEPARTMENT OF LABORATORIES Services & Procedures Update RPR (Rapid Plasma Reagin) PATHOLOGY RSV (Respiratory Syncytial Virus) PARASITOLOGY Anatomical Pathology Rupture of Fetal Membrane C. Difficile Toxin A/B Surgical pathology Strep A (Rapid Strep) Cryptosporidium Cytology Fecal Leukocyte Smear Bone Marrow GSA - Giardia Specific Antigen Fine Needle Aspirate BACTERIOLOGY Occult Blood (Stool) (both Bone Marrow and Fine Needle Aspirate Occult Blood (Gastric) must be scheduled Monday - Friday, 8 a.m. - 5 p.m.) Blood Cultures Direct AFB Strain pH (Stool) Fungus Culture Pin Worm Prep HEMATOLOGY Rotovirus Body Fluid Contact Gram Stain CBC or any part India Ink Crystal Exam KOH Prep MRSA Screen BLOOD BANK Differential (WBC) Antibody Identification Nasal Eosinophil Smear MRSA by PCR Routine Aerobic C/S Cord Blood Study (Type, Rh, DAT) Reticulocyte Count Compatibility Testing (Crossmatch) Sedimentation Rate Routine Anaerobic Stool Culture Component Therapy Spinal Fluid Exam Red Blood Cells Urease Test for H. pylori Platelets FFP COAGULATION URINALYSIS Cryoprecipitate D-Dimer DAT (Direct Antiglobulin Test) Fibrinogen Body Fluid pH Clinitest for reducing substances, urine Neonatal Type and DAT Prothrombin time Rhogam Screen PTT Complete Urinalysis or any part Eosinophil Count (Urine) (Includes Fetal Bleed Screen) PFS (Platelet Function Screen) Transfusion Reaction Workup (Recommended Instead of Bleeding Time) Specific Gravity - Refractometer Type and Rh Rotem Wet Prep KOH (vaginal, penile) Type and Screen SEROLOGY Cold Agglutinin Screen Fetal Fibronectin Group B Strep Latex (CSF, Serum) HCG - Urine/Serum HIV Screen (Employee/Inpatient Only) Influenza A/B Meningitis Panel CSF Serum Urine (Except Group B Strep) Mono Test Osmolality (Serum and Urine) RA (Rheumatoid Factor) For further information, please contact the North Oaks Department of Laboratories at (985)230-6165..
Load more

Recommended publications
  • The Association of Ffn Testing on Hospital Admissions for Preterm Labor*
    Open Journal of Obstetrics and Gynecology, 2013, 3, 126-129 OJOG doi:10.4236/ojog.2013.31024 Published Online January 2013 (http://www.scirp.org/journal/ojog/) The association of fFN testing on hospital admissions for * preterm labor Shilpa Iyer#, Thomas McElrath, Petr Jarolim, James Greenberg Brigham and Women’s Hospital, Harvard Medical School, Boston, USA Email: #[email protected] Received 5 November 2012; revised 7 December 2012; accepted 16 December 2012 ABSTRACT 1. INTRODUCTION Objective: To determine if the use of fetal fibronectin Preterm births continue to be the leading cause of infant (fFN) testing has affected hospital admissions for pre- mortality in the United States. While the infant mortality term labor. Methods: ICD-9 and CPT codes from all rate has plateaued from 2000 until the present, the per- admissions to Brigham & Women’s Hospital between centage of preterm births has increased. In 2005, 68.6% January 1, 1995 and December 31, 2010 were evaluated. of infant deaths were in preterm infants, an increase from Data recorded included total deliveries, admissions 65.6% in 2000 [1]. Along with increased rates in prema- for preterm labor (PTL) without delivery, length of turity, the cost of health care continued to skyrocket from stay (days) for PTL admissions, preterm deliveries, 2000 to 2005, and continues to increase today. In 2008, and number of fFN tests performed. The data was health care spending accounted for 16.2% of the United evaluated using a Wilcoxon test of trend and least States Gross Domestic Product, surpassing 2.3 trillion squares regression. Results: Fetal fibronectin testing dollars.
    [Show full text]
  • Rapid Ffn® Test Specimen Collection Kit
    Rapid fFN® Test Specimen Collection Kit PRD-01020 For In Vitro Diagnostic Use Only Store at 2° to 25°C. To be used by trained medical personnel only. The Hologic Rapid fFN Specimen Collection Kit is for use with the Rapid fFN® Tests ® ® ® (PeriLynx™ System, Rapid fFN 10Q System and Rapid fFN for the TLiIQ System). INTENDED USE The Rapid fFN® Test Specimen Collection Kit contains specimen collection devices consisting of a sterile, polyester-tipped swab and a specimen transport tube containing 1 mL extraction buffer. This specimen collection device is intended for collection of cervicovaginal ® ® ® specimens for the Rapid fFN Tests (PeriLynx™ System, Rapid fFN 10Q System and Rapid fFN for the TLiIQ System). Specimens should be obtained only during a speculum examination. PRECAUTIONS AND WARNINGS 1. For in vitro diagnostic use only. 2. Do not use kit if swab package integrity is compromised or if specimen transport tubes have leaked. 3. The extraction buffer is an aqueous solution containing protease inhibitors and protein preservatives including aprotinin, bovine serum albumin, and sodium azide. Sodium azide may react with plumbing to form potentially explosive metal azides. Avoid contact with skin, eyes, and clothing. In case of contact with any of these reagents, wash area thoroughly with water. If disposing of this reagent, always flush the drain with large volumes of water to prevent azide build-up. 4. Specimens of human origin should be considered potentially infectious. Use appropriate precautions in the collection, handling, storage, and disposal of the specimen and the used kit contents. Discard used materials in a proper biohazard container.
    [Show full text]
  • Fetal Fibronectin Enzyme Immunoassay and Rapid Ffn® for the ® Tliiq System
    Fetal Fibronectin Enzyme Immunoassay and Rapid fFN® for the ® TLiIQ System INFORMATION FOR HEALTH CARE PROVIDERS A TEST TO AID IN THE ASSESSMENT OF PRETERM DELIVERY RISK This brochure was prepared by Hologic, Inc. to familiarize you with the clinical interpretation of ® the Fetal Fibronectin Enzyme Immunoassay or Rapid fFN for the TLiIQ System. In conjunction with other clinical information, testing for the presence of fetal fibronectin in cervicovaginal secretions of women with suspected preterm labor and women undergoing routine prenatal care will help you and your patients gain valuable information about their pregnancies, including assessment of risk of preterm delivery. Additional copies of this brochure are available by calling 1-888-PRETERM or +1 (508) 263-2900. INTENDED USE The Fetal Fibronectin Enzyme Immunoassay and Rapid fFN for the TLiIQ System are devices to be used as an aid in assessing the risk of preterm delivery in ≤ 7 or ≤ 14 days from the time of cervicovaginal sample collection in pregnant women with signs and symptoms of early preterm labor, intact amniotic membranes, and minimal cervical dilatation (< 3 cm), sampled between 24 weeks, 0 days and 34 weeks, 6 days gestation. The negative predictive values of the Fetal Fibronectin Enzyme Immunoassay of 99.5% and 99.2%, for delivery in ≤ 7 and ≤14 days, respectively, make it highly likely that delivery will not occur in these time frames. In addition, although the positive predictive values were found to be 12.7% and 16.7% for delivery in ≤ 7 and ≤ 14 days, respectively, this represents an approximate 4-fold increase over the reliability of predicting delivery given no test information.
    [Show full text]
  • Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2
    animals Review Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2. Fetomaternal Response to Infection and Novel Diagnostic Perspectives Paulina Jawor 1,* , John F. Mee 2 and Tadeusz Stefaniak 1 1 Department of Immunology, Pathophysiology and Veterinary Preventive Medicine, Wrocław University of Environmental and Life Sciences, 50-375 Wrocław, Poland; [email protected] 2 Animal and Bioscience Research Department, Teagasc, Moorepark Research Centre, P61 P302 Fermoy, County Cork, Ireland; [email protected] * Correspondence: [email protected] Simple Summary: Bovine perinatal mortality (death of the fetus or calf before, during, or within 48 h of calving at full term (≥260 days) may be caused by noninfectious and infectious causes. Although infectious causes of fetal mortality are diagnosed less frequently, infection in utero may also compromise the development of the fetus without causing death. This review presents fetomaternal responses to infection and the changes which can be observed in such cases. Response to infection, especially the concentration of immunoglobulins and some acute-phase proteins, may be used for diagnostic purposes. Some changes in internal organs may also be used as an indicator of infection in utero. However, in all cases (except pathogen-specific antibody response) non-pathogen-specific responses do not aid in pathogen-specific diagnosis of the cause of calf death. But, nonspecific markers of in utero infection may allow us to assign the cause of fetal mortality to infection and thus Citation: Jawor, P.; Mee, J.F.; increase our overall diagnosis rate, particularly in cases of the “unexplained stillbirth”. Stefaniak, T. Role of Infection and Immunity in Bovine Perinatal Abstract: Bovine perinatal mortality due to infection may result either from the direct effects of Mortality: Part 2.
    [Show full text]
  • Rapid Ffn® for the Tliiq® System Specimen Collection
    ® ® Rapid fFN for the TLiIQ System Specimen Collection Kit 71738-001 For In Vitro Diagnostic Use Only Store at 2° to 25°C. To be used by trained medical personnel only INTENDED USE The Hologic Specimen Collection Kit test contains specimen collection devices consisting of a sterile polyester tipped swab and a specimen transport tube containing 1 mL extraction buff er. This specimen collection device is intended for collection of cervicovaginal specimens for Hologic's in vitro diagnostic test, Rapid fFN® (fetal fi bronectin) for the TLiIQ® System. Specimens should be obtained only during a speculum examination. PRECAUTIONS AND WARNINGS 1. For in vitro diagnostic use only. 2. Do not use kit if swab package integrity is compromised or if specimen transport tubes have leaked. 3. The extraction buff er is an aqueous solution containing protease inhibitors and protein preservatives including aprotinin, bovine serum albumin, and sodium azide. Sodium azide may react with plumbing to form potentially explosive metal azides. Avoid contact with skin, eyes, and clothing. In case of contact with any of these reagents, wash area thoroughly with water. If disposing of this reagent, always fl ush the drain with large volumes of water to prevent azide build-up. 4. Specimens of human origin should be considered potentially infectious. Use appropriate precautions in the collection, handling, storage, and disposal of the specimen and the used kit contents. Discard used materials in a proper biohazard container. 5. Specimens for fetal fi bronectin testing should be collected prior to collection of culture specimens. Collection of vaginal specimens for microbiologic culture frequently requires aggressive collection techniques that may abrade the cervical or vaginal mucosa and may potentially interfere with sample preparation.
    [Show full text]
  • A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
    ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction ..............................................................................................................
    [Show full text]
  • Tests for the Evaluation of Preterm Labor and Premature Rupture of Membranes
    Medical Coverage Policy Effective Date ............................................. 7/15/2021 Next Review Date ....................................... 7/15/2022 Coverage Policy Number .................................. 0099 Tests for the Evaluation of Preterm Labor and Premature Rupture of Membranes Table of Contents Related Coverage Resources Overview .............................................................. 1 Recurrent Pregnancy Loss: Diagnosis and Treatment Coverage Policy ................................................... 1 Ultrasound in Pregnancy (including 3D, 4D and 5D General Background ............................................ 2 Ultrasound) Medicare Coverage Determinations .................. 13 Coding/Billing Information .................................. 13 References ........................................................ 15 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ
    [Show full text]
  • Plasma Levels of Cellular Fibronectin in Diabetes
    Pathophysiology/Complications ORIGINAL ARTICLE Plasma Levels of Cellular Fibronectin in Diabetes SUZAN D.J.M. KANTERS, MD, PHD RINI C.J.M. FRIJNS, MD contain an extra type III structural domain JAN-DIRK BANGA, MD, PHD JAAP J. BEUTLER, MD, PHD called ED-A (3,4). Usually, Ͻ1–2% of total ALE ALGRA, MD, PHD ROB FIJNHEER, MD, PHD fibronectins in plasma consists of this cellu- lar fibronectin (5). Elevated plasma levels of cellular fibro- nectin have been reported in patients with rheumatoid vasculitis, in preeclamptic OBJECTIVE — Cellular fibronectin is an endothelium-derived protein involved in suben- women, in patients with collagen vascular dothelial matrix assembly. Elevated plasma levels of cellular fibronectin therefore reflect loss disorders, in acute trauma, in sepsis syn- of endothelial cell polarization or injury to blood vessels. Consequently, elevated plasma lev- drome, and in thrombotic thrombocy- els of circulating cellular fibronectin have been described in clinical syndromes with vascular damage, although not in diabetes or atherosclerosis. topenic purpura (5–9). These observations suggest that the intravascular accumulation RESEARCH DESIGN AND METHODS — We determined fibronectin levels in 52 of cellular fibronectin reflects injury to blood patients with type 1 diabetes, 50 patients with type 2 diabetes, 54 patients with a history of vessels. Vessel wall damage with character- ischemic stroke, 23 patients with renal artery stenosis, and 64 healthy subjects. istic endothelial extracellular matrix changes is also found in subjects with diabetes. The RESULTS — Circulating cellular fibronectin was significantly elevated in patients with dia- accumulation of proteins in the suben- betes (4.3 ± 2.8 µg/ml) compared with patients with ischemic stroke (2.0 ± 0.9 µg/ml), patients dothelial matrix in patients with diabetes is with renovascular hypertension (1.7 ± 1.1 µg/ml), and healthy subjects (1.4 ± 0.6 µg/ml).
    [Show full text]
  • Section 13. Laboratory Considerations
    Section 13. Laboratory Considerations Table of Contents 13.1 Overview and General Guidance 13.2 Specimen Labeling 13.3 Procedures for Specimens That Cannot be Evaluated 13.4 Use of LDMS 13.5 Documentation 13.6 Urine Testing 13.6.1 Specimen Collection 13.6.2 Pregnancy Testing 13.6.3 Chlamydia and Gonorrhea Testing 13.6.4 Urine Culture 13.7 Blood Testing 13.7.1 Specimen Collection and Initial Processing 13.7.2 HIV Testing 13.7.3 Syphilis Testing 13.7.4 Hematology Testing 13.7.5 Serum Chemistries 13.7.6 Plasma Storage 13.7.7 CD4+ T Cell Count 13.7.8 HIV RNA PCR 13.7.9 HIV DNA PCR 13.8 Testing of Vaginal and Cervical Specimens 13.8.1 Vaginal pH 13.8.2 Wet Mount for Candidiasis and BV 13.8.3 Rapid Test for Trichomoniasis 13.8.4 Vaginal Gram Stain 13.8.5 Papanicolaou (Pap) Test 13.8.6 Self-Administered Vaginal Swabs for PK and biomarker testing 13.8.7 Endocervical Swabs for Biomarker Analysis 13.8.8 Intra-Vaginal Ring Storage 13.8.9 Herpes Lesion Testing Table 13-1 Volume Guide for Plasma Storage Appendix 13-1 Overview of Laboratory Testing Locations, Specimens, and Methods for MTN-020 Appendix 13-2 MTN-020 Lab Specimen Processing Guidelines Appendix 13-3 LDMS Specimen Management Guide to Logging in MTN-020 Specimens Appendix 13-4 MTN-020 HIV Testing Algorithms Appendix 13-5 MTN Network Lab HIV Query Form Appendix 13-6 LDMS Tracking Sheets This section contains information on the laboratory procedures performed in MTN-020.
    [Show full text]
  • Use of the Diagnostic Bacteriology Laboratory: a Practical Review for the Clinician
    148 Postgrad Med J 2001;77:148–156 REVIEWS Postgrad Med J: first published as 10.1136/pmj.77.905.148 on 1 March 2001. Downloaded from Use of the diagnostic bacteriology laboratory: a practical review for the clinician W J Steinbach, A K Shetty Lucile Salter Packard Children’s Hospital at EVective utilisation and understanding of the Stanford, Stanford Box 1: Gram stain technique University School of clinical bacteriology laboratory can greatly aid Medicine, 725 Welch in the diagnosis of infectious diseases. Al- (1) Air dry specimen and fix with Road, Palo Alto, though described more than a century ago, the methanol or heat. California, USA 94304, Gram stain remains the most frequently used (2) Add crystal violet stain. USA rapid diagnostic test, and in conjunction with W J Steinbach various biochemical tests is the cornerstone of (3) Rinse with water to wash unbound A K Shetty the clinical laboratory. First described by Dan- dye, add mordant (for example, iodine: 12 potassium iodide). Correspondence to: ish pathologist Christian Gram in 1884 and Dr Steinbach later slightly modified, the Gram stain easily (4) After waiting 30–60 seconds, rinse with [email protected] divides bacteria into two groups, Gram positive water. Submitted 27 March 2000 and Gram negative, on the basis of their cell (5) Add decolorising solvent (ethanol or Accepted 5 June 2000 wall and cell membrane permeability to acetone) to remove unbound dye. Growth on artificial medium Obligate intracellular (6) Counterstain with safranin. Chlamydia Legionella Gram positive bacteria stain blue Coxiella Ehrlichia Rickettsia (retained crystal violet).
    [Show full text]
  • Syphilis Diagnosis: Three Cases with Increasing Treponemal Test Result After Therapy
    Acta Derm Venereol 2014; 94: 323–324 SHORT COMMUNICATION Syphilis Diagnosis: Three Cases with Increasing Treponemal Test Result after Therapy Henrik O. Larsson1*, Annika Johnsson2 and Anders Bredberg1 Departments of 1Medical Microbiology, and 2Dermatology and Venereology, Skane University Hospital, Lund University, Jan Waldenströms gata 59, SE- 205 02 Malmö, Sweden. *E-mail: [email protected] Accepted May 4, 2013 Epub ahead of print Oct 3, 2013 Serology is a main tool for syphilis diagnostic work used (the Captia Syphilis-Enzywell Treponema IgG and IgM, (1–3). According to a recent survey performed by the respectively, EIA from Diesse, Monteriggioni, Italy); the IgG method uses antigen-coated wells and IgM is determined by U.S. Centers for Disease Control and Prevention (CDC) capture technique; a value over 1.0 is considered to be reactive 56% of infectious disease specialists responded that they (7). Particle agglutination was done at serum dilution 80 with send a rapid plasma reagin (RPR) test to the laboratory no quantitation of the result (TPPA, Fujirebio, Tokyo, Japan). and treat presumptively for syphilis (if result is negative 18% repeat the RPR testing before treating the patient, and 17% treat only if RPR is positive) (4). However, a RESULTS clearly positive reaction may be missing at the first visit Case 1 was tested twice, at 6 days before and 112 of patients with active syphilis (5). Non-treponemal test days after treatment start (Fig. 1, upper panel). The (e.g. RPR and Venereal Disease Research Laboratory treponemal screening value is rising from 4 to a highly (VDRL)) reactivity is known to decrease in response to reactive value of 14, while the non-treponemal VDRL therapy, in contrast to the typically life-long persistence titre decreases from a weak 1 to negativity.
    [Show full text]
  • Medical Bacteriology
    LECTURE NOTES Degree and Diploma Programs For Environmental Health Students Medical Bacteriology Abilo Tadesse, Meseret Alem University of Gondar In collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education September 2006 Funded under USAID Cooperative Agreement No. 663-A-00-00-0358-00. Produced in collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education. Important Guidelines for Printing and Photocopying Limited permission is granted free of charge to print or photocopy all pages of this publication for educational, not-for-profit use by health care workers, students or faculty. All copies must retain all author credits and copyright notices included in the original document. Under no circumstances is it permissible to sell or distribute on a commercial basis, or to claim authorship of, copies of material reproduced from this publication. ©2006 by Abilo Tadesse, Meseret Alem All rights reserved. Except as expressly provided above, no part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission of the author or authors. This material is intended for educational use only by practicing health care workers or students and faculty in a health care field. PREFACE Text book on Medical Bacteriology for Medical Laboratory Technology students are not available as need, so this lecture note will alleviate the acute shortage of text books and reference materials on medical bacteriology.
    [Show full text]